Project Grant R01DA065085
Award Date 8/15/26
Completion Date 5/31/31
Dollars Obligated $699K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- The National Institute on Drug Abuse awarded The Johns Hopkins University $1.731 million on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on immune mechanisms impacting the blood-brain barrier in people who inject drugs with and without HIV. The research examines how neuroimmune-blood-brain-barrier interactions contribute to cognitive complications among people with a history of injection drug use, particularly those coinfected with HIV....
- The National Institute on Drug Abuse awarded the University of Maryland, Baltimore $1,371,874 under the Drug Use and Addiction Research Programs (CFDA 93.279) on March 15, 2026, to investigate the impact of opioid use disorder on mitochondrial dysfunction among antiretroviral therapy-receiving aging people with HIV. The research addresses a gap in understanding how long-term antiretroviral therapy and opioid use disorder compound inflammaging—a low-grade chronic proinflammatory immune...
- The National Institute on Drug Abuse awarded the University of California, San Diego $1,387,755 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate mitochondrial oxidative phosphorylation dysregulation in HIV-associated neurocognitive disorder and opioid use disorder, with NAD+ treatment as a potential therapeutic strategy. The research establishes a three-dimensional human assembloid model composed of iPSC-derived neurons, astrocytes, microglia, and...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $668,423 under Project Grant R61DA066158 on April 15, 2026, to conduct integrated research on microglial mechanisms in HIV persistence and methamphetamine-induced neuroinflammation. The award funds research combining transcriptomic and proteomic analyses with advanced human-derived models to map and validate MECOM (MDS1 and EVI1 complex locus protein)–associated signaling networks in HIV-infected microglia exposed to...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a $439,180 Project Grant effective September 1, 2025, through August 31, 2027, under the Drug Use and Addiction Research Programs (CFDA 93.279). This R21 exploratory/developmental grant supports research investigating dopaminergic neuronal-glial interactions in the striatum, with specific focus on understanding how HIV replication and methamphetamine exposure alter communication between...
- The National Institute on Drug Abuse awarded Thomas Jefferson University $723,388 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate mechanisms regulating central nervous system viral load and reservoir in the context of HIV infection and cocaine use comorbidity. The funded research addresses how DNA-dependent protein kinase mediates transcription-coupled repair during HIV transcription in microglia, the major HIV reservoir in the central nervous...
- The National Institute on Drug Abuse, part of the Department of Health and Human Services National Institutes of Health, awarded the University of California, San Diego $192,930 in project grant funding on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports mentoring in patient-oriented research on central nervous system dysfunction in individuals with HIV and substance use. The funded activities provide protected time for the principal...
- The National Institute on Drug Abuse awarded Meharry Medical College $400,125 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate neuronal mitochondrial dysfunction and microglial HIV reservoirs in African Americans with nicotine addiction and viral suppression. The research addresses accelerated neurocognitive aging in African Americans living with HIV despite effective antiretroviral therapy. The project examines how persistent microglial HIV...
- The National Institute on Drug Abuse, a component of the Department of Health and Human Services, awarded Drexel University $684,123 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the role of inflammasomes in the neurobehavioral and transcriptomic effects of cocaine exposure and HIV infection. The research addresses cocaine use disorder in people living with HIV, a population experiencing exacerbated risk for behavioral and cognitive deficits...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $2.352 million on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct single-molecule functional validation of neurogenomic alterations in opioid-exposed HIV brain tissue. The project performs single-molecule fiber-seq profiling on cingulate cortex tissue samples from the SCORCH (Single Cell Opioid Response in the Context of HIV) consortium, analyzing approximately...